Migraine Drugs Market PPT: Opportunities by Types, Demand, Top Manufactures and Application in Grooming Regions

1
Global Migraine Drugs Market Research and
Forecast Report 2021-2026




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Migraine Drugs Market Research
Report According to the latest report by IMARC
Group, titled Migraine Drugs Market Global
Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2021-2026, the global migraine
drugs market reached a strong growth in
2020.  Migraine drugs refer to medications that
are used to reduce the severity of migraines and
prevent future attacks. A migraine is a severe,
neurological disease with a debilitating
headache, characterized by an intense throbbing
or pulsing in one area of the head. It is
accompanied by sensitivity to light, sound and
smell, visual disturbances such as auras, and
nausea or vomiting. Migraine drugs do not cure
migraines instead, they treat or relieve these
symptoms. There are certain blood pressure
medications, as well as some antidepressants,
anti-seizure drugs and herbals that are used to
reduce the frequency of migraines. Request Free
Sample Report https//www.imarcgroup.com/migraine
-drugs-market/requestsample
4
Report Description and Highlights
Report Description
Global Migraine Drugs Market Trends According
to the Migraine Trust, migraine is the third most
common disease globally, with more than 10 of
people getting affected by the condition
worldwide. This represents the primary factor
that has increased the demand for migraine drugs
across the globe. Apart from this, the rising
healthcare expenditure and improving
reimbursement policies for migraine medications
are also acting as growth-inducing factors.
Besides this, healthcare providers have made
significant advancements in the diagnosis and
treatment of migraine. A more advanced
treatment modality with mechanism-based
therapies, including supraorbital transcutaneous
stimulation (STS) and transcranial magnetic
stimulation, has been introduced as a preventive
therapy for migraine. Additionally, there are
many other drugs with novel mechanisms of action
or new therapeutic targets, which are in
different development stages. Furthermore, for
the treatment of the coronavirus disease
(COVID-19), market players are testing migraine
drugs, which is expected to positively influence
the market. For instance, a clinical-stage
biopharmaceutical company, Biohaven
Pharmaceutical Holding Company Ltd., has been
examining Zavegepant to treat acute migraines and
has commenced the clinical trial on the same drug
to mitigate the neuro-immune consequences among
COVID-19 patients. Looking forward, the market
value is projected to reach a strong growth
during the forecast period (2021-2026).

5
Report Description and Highlights
Report Description

• Market Summary
• Breakup by Treatment Type
• Abortive Treatment
• Preventive Treatment
•  
• Breakup by Drug Type
• Triptans
• Ergot Alkaloids
• NSAIDs
• Acetylcholine Inhibitors/ Neurotoxins
• Ditans
• CGRP mAbs
• Others
• Breakup by Route of Administration
• Oral
• Injectable
• Others

6
Report Description and Highlights
Report Description

• Breakup by Distribution Channel
• Hospital-Based Pharmacies
• Retail Pharmacies
• Others
• Breakup by Region
• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany

7
Report Description and Highlights
Report Description

• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Argentina
• Columbia
• Chile
• Peru
• Others
• Middle East and Africa Turkey
• Saudi Arabia
• Iran
• United Arab Emirates
• Others

8
Report Description and Highlights
Report Description

• Note We are updating our reports, If you want
  latest primary and secondary data (2021-2026)
  with Cost Module, Business Strategy, Distribution
  Channel, etc. Click request free sample report.
• Competitive Landscape with Key Players
• Abbott Laboratories
• Allergan Plc (Abbvie Inc.)
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc. (formerly Valeant
  Pharmaceuticals)
• Eisai Co. Ltd.
• Eli Lilly and Company
• Endo International Plc
• GlaxoSmithKline Plc
• Johnson Johnson
• Merck Co.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Limited.

9
Report Description and Highlights
Report Description

View Full Report with TOC List of Figure
https//www.imarcgroup.com/migraine-drugs-market
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
12
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
13

Contact Us